SecBot SecBot

KMDA drug pipeline

KAMADA LTD · 2 rated drugs
$8.11
+0.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready FDA-approved and commercially marketed

CYTOGAM cytomegalovirus immune globulin intravenous (human) Updated Jul 13

What to watch

CYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.

Bull case
  • Sole FDA-approved CMV hyperimmune globulin for transplant, no direct approved competitor in the US market, giving Kamada an effective monopoly in this niche
  • Revenue growing strongly: CYTOGAM sales reached $22.5M in 2024, up 31% YoY (per Kamada's 2024 annual results)
  • Kamada received FDA approval to manufacture CYTOGAM in-house (May 2023), improving vertical integration and margins at the Beit Kama facility
Bear case
  • Small contributor to Kamada's overall business: CYTOGAM's ~$22.5M is only ~12-13% of total 2024 revenue of $180.5M, making it a minority driver of the stock
  • No near-term binary catalyst, SHIELD study primary completion is December 2027, no upcoming PDUFA or pivotal readout within 12 months
  • Competition from standard-of-care oral antivirals (valganciclovir/ganciclovir) is well-established, and CYTOGAM is an adjunctive add-on, not a standalone replacement
● neutral
Impact
PhaseApproved and marketed
Time to marketAlready approved and commercialized. No additional regulatory steps are needed for the current indication.

HEPAGAM hepatitis B immune globulin (human) Updated Nov 11

What to watch

HEPAGAM is a steady commercial product within a diversified portfolio, not a binary catalyst. Kamada's next major event is the Q4/full-year 2026 earnings report in early 2027, where investors will watch for continued demand trends across the product portfolio including HEPAGAM. The stock trades at $8.13 with a mean analyst target of $13.50, but the recent insider selling and institutional trimming warrant monitoring.

Bull case
  • HEPAGAM is part of a growing commercial portfolio that drove Kamada to record-high first nine months 2026 results, with the company raising full-year guidance to $205M-$208M in revenue.
  • Kamada's plasma-derived product portfolio benefits from strong demand trends, with HEPAGAM specifically cited alongside KEDRAB and VARIZIG as supporting the company's performance in 2026.
  • Analyst consensus is strongly bullish on KMDA (3 strong buy, 5 buy, 1 hold) with a mean price target of $13.50, implying roughly 66% upside from the $8.13 close on November 11, 2026.
Bear case
  • HEPAGAM is a mature, approved product in a competitive hepatitis B immune globulin market with limited differentiation, facing potential competition from other HBIG products and hepatitis B vaccines.
  • HEPAGAM is just one of several products in Kamada's portfolio and does not individually drive the stock's valuation, limiting its impact as a catalyst.
  • Insider selling was detected in the 90-day lookback, including significant sales by director David Tsur (over 162,000 shares sold on September 8, 2026), which may signal insider caution.

Other drugs in filings and trials

no drug report yet

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Alpha 1-AntitrypsinPhase III, Efficacy and Safety of "Kamada-AAT for Inhalation"Phase 3Terminated98Feb 19, 2026